Protocols
19 protocol(s) meet the specified criteria
Disease Site: Non-Hodgkins Lymphoma
Protocol No.TitleStatus
ACCL1131A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)Open
ACCL1333A Phase III Randomized, Open Label, Multi-center Study on the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) Treated with Pegylated (PEG) L-AsparaginaseOpen
AMC-068Randomized, Phase II Trial of CHOP vs. Oral Chemotherapy with Concomitant Antiretroviral Therapy in Patients with HIV-associated Lymphoma in Sub-Saharan AfricaOpen
AMC-083Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies A Trial of the AIDS Malignancy Consortium (AMC)Open
BMT-CTN-0702LTContinued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients Who Have Enrolled on BMT CTN 0702 Open
C34005A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (+/- Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of TherapyOpen
CC-5013-NHL-008A phase 3b randomized study of lenalidomide (CC-5013) plus rituximab maintenance therapy followed by lenalidomide single-agent maintenance versus rituximab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma.Open (affiliates only)
COG-ANHL12P1A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117Open
GO29383A Phase Ib Study of the Safety and Pharmacology of Atezolizumab Administered with Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma or Atezolizumab Administered with Obinutuzumab or Tazemetostat in Patients with Relapsed/Refractory Diffuse Large B-Cell LymphomaOpen
LCCC0824Tissue Procurement For Hematolymphoid ConditionsOpen
LCCC0905Graft-Versus-Host Disease Solid Tissue ProcurementOpen
LCCC1229Developing a prospective lymphoma clinical cohort in MalawiOpen
LCCC1335A Single-Arm Phase II Clinical Trial of Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma in MalawiOpen
LCCC1524-ATLPhase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas after High Dose Therapy and Autologous Stem Transplantation (ATLAS)Open
LCCC1532-ATLPhase Ib/II Study of the Administration of T lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin’s Lymphoma and CD30+ Non-Hodgkin’s LymphomaOpen
LCCC1538Geriatric Assessment Reporting in Real Time (GARRT) in non-electively hospitalized older cancer patients: feasibility, impact, and clinician acceptance.Open
LCCC1704Assessing the Feasibility of Screening and Treating Anxiety and Depression in the Bone Marrow Transplant PopulationOpen
S1001A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-cell Lymphoma (DLBCL) Open (affiliates only)
SGNS40-001SGNS40-001 – A phase 1, open-label, dose-escalation study of SEA-CD40 in adult patients with advanced malignanciesOpen